Efficacy of moxifloxacin-based triple therapy to eradicate Helicobacter pylori infection

National Medical Journal of China

Volumn 90, Issue 2, 2010, Pages 87-91

  Wang, Cheng Dang ^a   Zhuang, Ze Hao ^a   Lu, Dong ^a   Li, Wen Qing ^a   Wu, Ting ^a   Chen, Yu Li ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Drug therapy, combination; Gastritis; Helicobacter pylori; Moxifloxacin; Peptic ulcer

Indexed keywords

ESOMEPRAZOLE; MOXIFLOXACIN; TINIDAZOLE; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ULCER; UREA BREATH TEST; ADULT; DRUG COMBINATION; EVALUATION; FEMALE; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES;

EID: 84871444557     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.02.006     Document Type: Article

References (21)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007, 56:772-781.
2. 2008, 88:652-656.
3. Graham D Y, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter, 2007, 12:275-278.
4. Jodlowski T Z, Lam S, Ashby C R Jr. Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother, 2008, 42:1621-1639.
5. Vilaichone R K, Mahachai V, Graham D Y. Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am, 2006, 35:229-247.
6. 2007, 12:525-530.
7. Kumala W, Rani A. Patterns of Helicobacter pylori isolate resistance to fluoroquinolones, amoxicillin, clarithromycin and metronidazoles. Southeast Asian J Trop Med Public Health, 2006, 37:970-974.
8. Hung K H, Sheu B S, Chang W L, et al. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter, 2009, 14: 61-65.
9. Kim J M, Kim J S, Kim N, et al. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents, 2006, 28:6-13.
10. Kang J M, Kim N, Lee D H, et al. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter, 2007, 12:623-628.
11. Cheon J H, Kim N, Lee D H, et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter, 2006, 11:46-51.
12. 2008, 17:106-109.
13. Villoria A, Garcia P, Calvet X, et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther, 2008, 28:868-877.
14. Fischbach L, Evans E L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther, 2007, 26:343-357.
15. Kist M. How effective is moxifloxacin for the first-line treatment of patients with Helicobacter pylori infection? Nat Clin Pract Gastroenterol Hepatol, 2005, 2:450-451.
16. Cattoir V, Nectoux J, Lascols C, et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int Antimicrob Agents, 2007, 29: 389-396.
17. Nista E C, Candelli M, Zocco M A, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther, 2005, 21: 1241-1247.
18. Bago J, Pevec B, Tomić M, et al. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr, 2009, 121:47-52.
19. Miehlke S, Schneider-Brachert W. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter, 2008, 13:69-74.
20. Kiliç Z M, Köksal A S, Cakal B, et al. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Dig Dis Sci, 2008, 53: 3133-3137.
21. Kim J M, Kim J S, Kim N, et al. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemotherapy, 2005, 56:965-967.